Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)TransplantationDiseaseAcute Myeloid LeukemiaMyelodysplastic NeoplasmsStem Cell Transplantation, AllogeneicSubgroupCD33+FLT3 mutationFLT3-ITDHigh riskIDH1-MutationTP53 mutationICD10C92.0-C92.5-C92.6-C92.7-C92.8-C92.9-C93.0-D46.-MeSHLeukemia, Monocytic, AcuteLeukemia, MyeloidLeukemia, Myeloid, AcuteMyelodysplastic SyndromesSequenceALFA-0701, AMLCLAG-Ida (CLAD5/CYTA2000/IDAR12/FILG300), AML, Ind. (PID2220) -|- CLAG-Ida (CLAD5/CYTA2000/IDAR12/FILG300), Cons. (PID2221)CLAG-M, r/r AML, Polish Adult Leukemia GroupDAUN60/CYTA200, AML ind. (PID1825) -|- HD CYTA 3000, AML cons., below 60, d1,3,5 (PID516)DAUN60/CYTA200/MDST50, AML Ind. (PID1079) -|- Cons. (PID1080) -|- maint. (PID1081)DECI15, AML, C1-4 (PID2321) -|- DECI20, C5+ (PID2322)EORTC-GIMEMA AML-19: GEMOZO(6/3), AML, ind. (PID2590) -|- GEMOZO2, cons. (PID2591)FLAGIDA (FLUD30/CYTA1500/IDAR8)/VNTC400, AML, Ind. (PID2522) -|- Cons. (PID2524)HOVON 132 AML / SAKK 30/13, Arm AHOVON 132 AML / SAKK 30/13, Arm BLDAUN-LCYTA144, AML Ind., C1 (PID1414) -|- C2 (PID1426) -|- cons. (PID1427)QuANTUM-First: DAUN60/CYTA100/QUIZ35.4, AML, Ind. (PID2551) -|- Cons. (PID2553) -|- maint., C1 (PID2554) -|- maint., C2+ (PID2555)QuANTUM-First: IDAR12/CYTA100/QUIZ35.4, AML, Ind. (PID2552) -|- Cons. (PID2553) -|- maint., C1 (PID2554) -|- maint., C2+ (PID2555)SAL Study Group, AMLSORMAIN: SORA400/600, AML, maint., C1 (PID1020) -|- SORA800, C2+ (PID1038)STUDY-AMLSG, Investigational armSTUDY - Dauno DoubleSTUDY AMLSG, Standard armTAD-HAM: TAD (TIOG100/CYTA60/DAUN100), AML ind. below 60 (PID519) -|- HAM (CYTA3000/MXNT10), AML ind. below 60 (PID596)VNTC(100/200/300/400/600)/CYTA20, AML, from 60 y., C1 (PID1260) -|- VNTC600/CYTA20, AML, from 60 y., C2+ (PID1319)VNTC(100/200/400)/AZCT75, AML, C1 (PID1595) -|- VNTC400/AZCT75, AML, C2+ (PID1596)VNTC(100/200/400)/DECI20, AML, C1 (PID1597) -|- VNTC400/DECI20, AML, C2+ (PID1598)VNTC(100/200/400)/GILT120, AML, C1 (PID2148) -|- VNTC400/GILT120, C2+ (PID2149)ChemotherapyChemo-substanceAmsacrineAzacitidineCladribineCytarabineDaunorubicinDaunorubicin-cytarabine liposomalDecitabineEtoposideFludarabineGemtuzumab OzogamicinGilteritinibGlasdegibHydroxyureaIdarubicinIvosidenibLenalidomideMelphalanMidostaurinMitoxantroneQuizartinibSorafenibTioguaninVenetoclaxChemo-substanceAmsacrineAzacitidineCladribineCytarabineDaunorubicinDaunorubicin-cytarabine liposomalDecitabineEtoposideFludarabineGemtuzumab OzogamicinGilteritinibGlasdegibHydroxyureaIdarubicinIvosidenibLenalidomideMelphalanMidostaurinMitoxantroneQuizartinibSorafenibTioguaninVenetoclaxChemo-substanceAmsacrineAzacitidineCladribineCytarabineDaunorubicinDaunorubicin-cytarabine liposomalDecitabineEtoposideFludarabineGemtuzumab OzogamicinGilteritinibGlasdegibHydroxyureaIdarubicinIvosidenibLenalidomideMelphalanMidostaurinMitoxantroneQuizartinibSorafenibTioguaninVenetoclaxChemo-substanceAmsacrineAzacitidineCladribineCytarabineDaunorubicinDaunorubicin-cytarabine liposomalDecitabineEtoposideFludarabineGemtuzumab OzogamicinGilteritinibGlasdegibHydroxyureaIdarubicinIvosidenibLenalidomideMelphalanMidostaurinMitoxantroneQuizartinibSorafenibTioguaninVenetoclaxNo. Substances1234 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronPantoprazoleParacetamolPegfilgrastimPosaconazolePrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronPantoprazoleParacetamolPegfilgrastimPosaconazolePrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronPantoprazoleParacetamolPegfilgrastimPosaconazolePrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronPantoprazoleParacetamolPegfilgrastimPosaconazolePrednisoloneNo. Substances123456789Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityhigh doseLow doseStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseconditioningConsolidationInductionMaintenanceReinductionSalvageTherapy intentioncurativecurative or palliativepalliativeRisksAlopeciaAnemia Hb below 8g/dlArthalgiaAstheniaBleedingCardiotoxicityCMV Infection (asympt. + sympt.)CNS ToxicityColitisConstipationDiarrheaDifferentiation syndromeDyspneaEdemaElectrolyte DisturbanceEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityHeadacheHemorrhageHepatotoxicityHyperbilirubinemiaHyperglycemiaHyperkalemiaHypertensionHypocalcemiaHypoglycemiaHypokalemiaHyponatremiaHypophosphatemiaIncrease AminotransferasesInfectionsLeukopeniaLymphopeniaMucositisMyalgiasNauseaNephrotoxicityNeuropathyNeutropeniaOral MucositisPainPneumoniaPyrexiaQTc Time ExtensionRashRenal FailureSeizuresSepsisThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract InfectionVOD/SOS only studiesPublicationAuthorAmadori SB. LöwenbergBraess JBurchert ABurnett ABurnett AKBüchner TCortes JECraddock CDaver NDiNardo CDDombret HErba HPFong CFridle CGaidzik VHolowieki JJaramillo SKantarjian HMLambert JLancet JELevis MJLöwenberg BLübbert MMayer RJMontesinos PParker JPerl APlatzbecker UPrice SRöllig CSchaich MSchroeder TSeiter KSperr WRStone RStone RMStratmann JThiel AVellenga EWang ESWei AWei AHWelch JWierzbowska AYates JWDiseaseAkute myeloische Leukämie, RezidivtherapieAML (Doppel-)InduktionAML, Alter ab 55 J., CR/CRi nach Induktion, nicht für eine HSZT geeignet, ECOG 0-3AML, CD33 positiv, rezidiviertAML, Erstlinie Induktion, ECOG 0-4AML, Erstlinientherapie, für eine Standardtherapie nicht geeignet, ECOG 0-2AML, FLT3-ITD positiv, komplette hämatologische Remission nach allogener SCTAML, FLT3-Mutation (ITD oder TKD), mind. 1 Vortherapie, ECOG 0-2AML, neu diagnostiziertAML, neu diagnostiziert, FLT3-ITD+AML, nicht geeignet für intensive Chemotherapie, nicht vorbehandelt, Alter >65 J.AML, rezidiviert oder therapierefraktärAML, rezidiviert oder therapierefraktär, IDH-1-mutiert, ECOG 0-2AML- oder CMML-Rezidiv nach allogener StammzelltranplantationAML- oder MDS-Rezidiv nach allogener StammzelltranplantationAML > 60 Jahre, rezidivierende AML oder transfusionspflichtiges MDS, ECOG 0-2AML KonsolidierungAML oder Hochrisiko MDS, nicht für eine Standard-Induktionschemotherapie geeignet, ECOG 0-2AML therapierefraktär oder Frührezidivde-novo oder sekundäre AML, mindestens 1 nicht-kurative Vortherapie, über 65 JahreDecitabin für Patienten ab 61 Jahren mit de novo oder sekundärer AML, für intensive Therapie nicht geeignet, ECOG 0-2Decitabin für Patienten ab 65 Jahren mit neudiagnostizierter de novo oder sekundärer AML, ECOG 0-2De novo oder sekundäre AML, Hochrisiko MDS, PS 0-4Drohendes AML- oder MDS-Rezidiv nach allogener Stammzelltranplantation (Spenderchimärismus <80%)FLT3-ITD+ AML nach allogener SCTHochrisiko MDS und AML, Rezidiv oder de novo MDSInduktion AMLneu-diagnostizierte AMLneu-diagnostizierte AML, intermediäres/ungünstiges genetischen Risiko (ELN 2017), ECOG 0-2neudiagnostizierte AML, CD33 positiv, Induktion, Erstlinieneudiagnostizierte AML, CD33 positiv, Induktion, Erstlinie, Leukozytenzahl < 30.000/µlneudiagnostizierte AML, CD33 positiv, Induktion, Erstlinie, Leukozytenzahl ab 30.000/µlneudiagnostizierte AML, CD33 positiv, Induktion, Erstlinie, Leukozytenzahl bis 30.000/µlneudiagnostizierte AML, ECOG 0-2neudiagnostizierte AML, Erhaltung bei Patienten in kompletter Remission, FLT3-Mutation, ErstlinieNeu diagnostizierte AML, FLT3+, nicht für eine intensive Therapie geeignet, ECOG 0-2Neu diagnostizierte AML, IDH-1-mutiert, nicht für eine intensive Therapie geeignet, ECOG 0-2neudiagnostizierte AML, Induktion, FLT3-Mutation, Erstlinieneudiagnostizierte AML, Konsolidierung, FLT3-Mutation, Erstlinieneudiagnostizierte AML, primär oder sekundär, Erstlinie, ECOG 0-2neudiagnostizierte de-novo oder sekundäre AML, ECOG 0-4Neu diagnostizierte de-novo oder sekundäre AML mit Knochenmarkblasten > 30%, Alter > 65 Jahre, ECOG 0-2neudiagnostizierte de novo oder sekundäre AML, 18-60 Jahre, ECOG < 3Neudiagnostizierte oder sekundäre, unbehandelte AMLneu diagnostizierte oder sekundäre AML, Alter ≥60 Jahreprimäre oder sekundäre AML, Erstdiagnose, 18-65, ECOG 0-2primär refraktäre oder rezidivierende AMLRezidivierte oder therapierefraktäre AML, ECOG 0-2Rezidivierte oder therapierefraktäre AML, FLT3 ITD oder TKD D835 oder I836 MutationOriginAbramson Cancer Center, University of Pennsylvania, USA, ADMIRAL StudieCancer and Leukemia Group BCarl Gustav Carus Technical University of Dresden, Dresden, Germany, RELAZA trialDana-Farber Cancer Institute, Boston, USADana-Farber Cancer Institute, Boston MADana-Farber Cancer Institute, Boston MA, RATIFY trialDepartment of Bone Marrow Transplantation, Comprehensive Cancer Center M. Curie- Sklodowska Memorial Institute, Branch Gliwice, PolandDepartment of Clinical Hematology, The Alfred Hospital, Melbourne, AustraliaDepartment of Haematological Medicine, King's College School of Medicine and Dentistry, LondonDepartment of Haematology, Cardiff University School of Medicine, UK, AML15 trialDepartment of Haematology, The Alfred Hospital, MelbourneDepartment of Haematology, Wales School of Medicine, Cardiff University, UK, Leukaemia Research Fund AML14Department of Hematology, University of Groningen and University Medical Center Groningen, HOVON/SAKK AML-29/42Department of Internal Medicine, Washington University School of MedicineDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany, AMLSGDepartment of Leukemia, Division of Cancer Medicine, University of Texas, Houston, USDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, HoustonDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USADepartment of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany, AML-CGDepartment of Pharmacy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USADivision Hematology and Oncology, University of Freiburg Medical Center, Freiburg, GermanyDuke Cancer Institute, Durham, USA, QuANTUM-First trialDutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK)East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL)German AML Cooperative GroupH. Lee Moffitt Cancer Center and Research Institute, Tampa, FLHematology and Oncology, Goethe University, Frankfurt, Frankfurt am Main, GermanyHospital Universitari i Politecnic La Fe, Valencia, AGILE trialHOVON / SAKKHOVON 132 AML / SAKK 30/13Hôpital Saint Louis, Institut Universitaire d´Hématologie, University Paris Diderot, Paris, FranceJohns Hopkins University, Baltimore, MDMedical University of Lodz, Lodz, PolandMedical University of Vienna, AustriaMedizinische Klinik und Poliklinik I, Universitätsklinikum DresdenMonash University, Melbourne, Australia, QUAZAR AML-001 trialNew York Medical College, Valhalla, United StatesOncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, GermanyPhilipps University Marburg and University Hospital Gießen and Marburg, Campus Marburg, Marburg, Germany, SORMAIN trialRoswellPark Comprehensive Cancer Center, Buffalo, NY, USA, LACEWING trialSAL - Studienallianz Leukämie Service d Hematologie et Oncologie, Centre Hospitalier de Versailles, ALFA-0701Study Alliance Leukemia, SAL, AML 2003 StudieThe University of Texas MD Anderson Cancer Center, Houston, TXTor Vergata University, EORTC-GIMEMA AML-19 TrialUlm University Hospital, Germany, AMLSG 30-18University Hospital Berne and University of Berne, Berne, SwitzerlandUniversity of Birmingham, Birmingham, United KingdomUniversity of Freiburg Medical Center, Freiburg, GermanyUniversity of Texas, MD Anderson Cancer Center, Houston, USAUniversity of Texas M.D. Anderson Cancer Center, Department of Leukemia, HoustonProtocols in Revision 89 protocols foundProtocols under revision.Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation (PID2302 V1.0)Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation, Variant 1. (PID2320 V1.0)Azacitidine 300, Acute Myeloid Leukemia (PID1807 V1.0)Azacitidine 75 / Gilteritinib 120, Acute Myeloid Leukemia (PID2430 V1.0)Azacitidine 75 / Ivosidenib 500, Acute Myeloid Leukemia (PID2368 V1.1)Azacitidine 75 / Lenalidomide 25, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation (PID827 V1.2)Azacitidine 75, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation. (PID2327 V1.0)Azacitidine 75, Acute Myeloid Leukemia, over 65 years of age (PID700 V1.2)Cladribine 5 / Cytarabine 2000 / Idarubicin 12 / Filgrastim 300, Acute Myeloid Leukemia, Induction (PID2220 V1.0)Cladribine 5 / Cytarabine 2000 / Idarubicin 12 / Filgrastim 300, Acute Myeloid Leukemia, consolidation (PID2221 V1.0)Cladribine 5 / Cytarabine 2000 / Idarubicin 8, Acute Myeloid Leukemia (PID2209 V1.1)Cladribine 5 / Cytarabine 2000 / Mitoxantrone 10 / Filgrastim 300, Acute Myeloid Leukemia (PID2203 V1.0)Cladribine 5 / Cytarabine 2000, Acute Myeloid Leukemia (PID2204 V1.0)Cladribine 5 / Daunorubicin 60 / Cytarabine 200, Acute Myeloid Leukemia (PID2436 V1.0)CLAG - Cladribine 5 / Cytarabine 2000 / Filgrastim 300, AML (PID859 V1.2)Cytarabine 1000, Acute Myeloid Leukemia, consolidation, over 60 years of age (PID601 V1.3)Cytarabine 1500 / Mitoxantrone 10, Acute Myeloid Leukemia (PID2208 V1.0)Cytarabine 1500, Acute Myeloid Leukemia, Consolidation (PID2574 V1.0)Cytarabine 20 / Glasdegib 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome (PID1674 V1.0)Cytarabine 20, Acute Myeloid Leukemia (PID833 V1.0)Cytarabine 3000 / Midostaurin 50, Acute Myeloid Leukemia, consolidation (PID1080 V1.4)Cytarabine 3000 / Quizartinib 35.4, Acute Myeloid Leukemia, consolidation (PID2553 V1.0)Cytarabine 3000, Acute Myeloid Leukemia, consolidation, under 60 years, day 1,3,5 (PID516 V1.3)Cytarabine 3000, Acute Myeloid Leukemia, consolidation, under 60 years, day 1-3 (PID995 V1.1)Daunorubicin 60 / Cytarabine 100 / Quizartinib 35.4, Acute Myeloid Leukemia, Induction (PID2551 V1.0)Daunorubicin 60 / Cytarabine 100, Acute Myeloid Leukemia, Induction (PID293 V1.2)Daunorubicin 60 / Cytarabine 200 / Midostaurin 50, Acute Myeloid Leukemia, Induction (PID1079 V1.2)Daunorubicin 60 / Cytarabine 200, Acute Myeloid Leukemia, induction (PID1825 V1.0)Daunorubicin Liposomal - Cytarabine liposomal 144, Acute Myeloid Leukemia, Induction, Cycle 1 (PID1414 V1.1)Daunorubicin Liposomal - Cytarabine liposomal 144, Acute Myeloid Leukemia, Induction, Cycle 2 (PID1426 V1.1)Daunorubicin Liposomal - Cytarabine liposomal 94, Acute Myeloid Leukemia, consolidation (PID1427 V1.0)Decitabine 15, Acute Myeloid Leukemia, cycle 1-4 (PID2321 V1.0)Decitabine 20, Acute Myeloid Leukemia (PID834 V1.2)Decitabine 20, Acute Myeloid Leukemia, First-Line (PID582 V1.2)Decitabine 20, Acute Myeloid Leukemia, cycle 5+ (PID2322 V1.0)FLAGAMSA (Fludarabine 30 / Cytarabine 2000 / Amsacrine 100), Acute Myeloid Leukemia (PID1710 V1.0)FLAGIDA - Fludarabine 30 / Cytarabine 2000 / Idarubicin 8, Acute Myeloid Leukemia (PID762 V1.2) (PID748 V1.2)FLAGIDA/Venetoclax - Fludarabine 30 / Cytarabine 1500 / Idarubicin 8 / Venetoclax 400, Acute Myeloid Leukemia, Induction (PID2522 V1.0)FLAGIDA/Venetoclax - Fludarabine 30 / Cytarabine 1500 / Idarubicin 8 / Venetoclax 400, Acute Myeloid Leukemia, Consolidation (PID2524 V1.0)Gemtuzumab Ozogamicin (6/3), Acute Myeloid Leukemia, Induction (PID2590 V1.0)Gemtuzumab Ozogamicin / Daunorubicin 35 / Cytarabine 1000, Acute Myeloid Leukemia, Induction, Cycle 2 (PID1 V1.1)Gemtuzumab Ozogamicin 2, Acute Myeloid Leukemia, consolidation (PID2591 V1.0)Gemtuzumab Ozogamicin 3 / Cytarabine 1000 / Daunorubicin 60, Acute Myeloid Leukemia, consolidation, cycle 1 (PID4 V1.0)Gemtuzumab Ozogamicin 3 / Cytarabine 1000 / Daunorubicin 60, Acute Myeloid Leukemia, consolidation, cycle 2 (PID5 V1.0)Gemtuzumab Ozogamicin 3 / Daunorubicin 60 / Cytarabine 200, Acute Myeloid Leukemia, Induction, Leukocyte count from 30,000/µl, Cycle 1 (PID3 V1.2)Gemtuzumab Ozogamicin 3 / Daunorubicin 60 / Cytarabine 200, Acute Myeloid Leukemia, Induction, Leukocyte count up to 30,000/µl, Cycle 1 (PID2 V1.2)Gilteritinib 120, Acute Myeloid Leukemia (PID1505 V1.1)Gilteritinib 120, Acute Myeloid Leukemia after allogeneic stem cell transplantation (PID2589 V1.0)High-dose Cytarabine 3000 / Mitoxantrone 10, Acute Myeloid Leukemia, induction less than 60 years of age (PID596 V1.2)High-dose Cytarabine 3000 / Mitoxantrone 10, sequential, Acute Myeloid Leukemia, induction, less than 60 years of age (PID603 V1.1)HOVON 132 AML / SAKK 30/13 - B - Idarubicin 12 / Cytarabine 200 / Lenalidomide 20, induction, Acute Myeloid Leukemia, cycle 1 (PID1065 V1.1)HOVON Daunorubicin 60 / Cytarabine 1000, induction, Acute Myeloid Leukemia, cycle 2 (PID1067 V1.1)HOVON Idarubicin 12 / Cytarabine 200, induction, Acute Myeloid Leukemia, cycle 1 (PID1064 V1.1)HOVON Mitoxantrone 10 / Etoposide 100, consolidation, Acute Myeloid Leukemia (PID1069 V1.1)Idarubicin 12 / Cytarabine 100 / Quizartinib 35.4, Acute Myeloid Leukemia, Induction (PID2552 V1.0)Idarubicin 12 / Cytarabine 1000, Acute Myeloid Leukemia, Induction, Cycle 2, salvage therapy (PID1247 V1.1)Ivosidenib 500, acute myeloid leukaemia (PID2369 V1.1)MAMAC - Cytarabine 2000 / Amsacrine 100, Acute Myeloid Leukemia (PID642 V1.0)MEC - Mitoxantrone 8 / Etoposide 100 / Cytarabine 1000, Acute Myeloid Leukemia (PID861 V1.2)Melphalan 2, Acute Myeloid Leukemia, over 65 years of age (PID1735 V1.1)Midostaurin 50, Acute Myeloid Leukemia, maintenance (PID1081 V1.1)Mito-FLAG - Fludarabine 15 / Cytarabine 1000 / Mitoxantrone 7, Acute Myeloid Leukemia (PID2521 V1.0)Quizartinib (26.5/53), Acute Myeloid Leukemia, maintenance, cycle 1 (PID2554 V1.0)Quizartinib 53, Acute Myeloid Leukemia, maintenance, cycle 2+ (PID2555 V1.0)Sorafenib 400/600, Acute Myeloid Leukemia, maintenance, cycle 1 (PID1020 V1.0)Sorafenib 800, Acute Myeloid Leukemia, maintenance, cycle 2+ (PID1038 V1.0)Study - DaunoDouble - Daunorubicin 45 / Cytarabine 100, AML Induction II, under 60 years of age (PID626 V1.1)Study - DaunoDouble - Daunorubicin 60 / Cytarabine 100, AML Induction I+II, under 60 years of age (PID627 V1.1)Study - DaunoDouble - Daunorubicin 90 / Cytarabine 100, AML Induction I, under 60 years of age (PID625 V1.1)Study - HOVON 132 AML / SAKK 30/13 - B - Daunorubicin 60 / Cytarabine 1000 / Lenalidomide 20, Induction, Acute Myeloid Leukemia, Cycle 2 (PID1066 V1.1)Study - HOVON 132 AML / SAKK 30/13 - Lenalidomide 10, maintenance, Acute Myeloid Leukemia (PID1068 V1.0)Study-AMLSG - Cytarabine 1000, Acute Myeloid Leukemia, consolidation, over 60 years of age (PID1814 V1.0)Study-AMLSG - Cytarabine 1500, Acute Myeloid Leukemia, consolidation, under 60 years of age (PID1813 V1.0)Study-AMLSG - Daunorubicin 50 / Cytarabine 1000, Acute Myeloid Leukemia, Induction II, under 60 years of age (PID1810 V1.0)Study-AMLSG - Daunorubicin 50 / Cytarabine 500, Acute Myeloid Leukemia, Induction II, over 60 years of age (PID1812 V1.0)Study-AMLSG - Daunorubicin 60 / Cytarabine 200, Acute Myeloid Leukemia, Induction I (PID1811 V1.0)Study-AMLSG - Daunorubicin Liposomal - Cytarabine liposomal 144, Acute Myeloid Leukemia, Induction I (PID1815 V1.0)Study-AMLSG - Daunorubicin Liposomal - Cytarabine liposomal 144, Acute Myeloid Leukemia, Induction II (PID1816 V1.0)Study-AMLSG - Daunorubicin Liposomal - Cytarabine liposomal 94, Acute Myeloid Leukemia, consolidation (PID1817 V1.0)TAD - Tioguanin 100 / Cytarabine 100 / Daunorubicin 60, AML induction, under 60 years of age (PID519 V1.1)Venetoclax (100/200/300/400/600) / Cytarabine 20, Acute Myeloid Leukemia, 60 years of age and older, Cycle 1 (PID1260 V1.1)Venetoclax (100/200/400) / Azacitidine 75, Acute Myeloid Leukemia, Cycle 1 (PID1595 V1.0)Venetoclax (100/200/400) / Decitabine 20, Acute Myeloid Leukemia, Cycle 1 (PID1597 V1.0)Venetoclax (100/200/400) / Gilteritinib 120, Acute Myeloid Leukemia, Cycle 1 (PID2148 V1.0)Venetoclax 400 / Gilteritinib 120, Acute Myeloid Leukemia, Cycle 2+ (PID2149 V1.0)Venetoclax 400 / Azacitidine 75, Acute Myeloid Leukemia, Cycle 2+ (PID1596 V1.0)Venetoclax 400 / Decitabine 20, Acute Myeloid Leukemia, Cycle 2+ (PID1598 V1.0)Venetoclax 600 / Cytarabine 20, Acute Myeloid Leukemia, 60 years and older, cycle 2+ (PID1319 V1.1)
